clinical trial · NCT05053321
Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine
Yale University·phase1·withdrawn
Tardive DyskinesiaValbenazine
brief summary
This will be an Investigator-initiated pilot study in which participants will be assessed with various scales to measure demoralization, anxiety, depression, and subjective incompetence at baseline and every two weeks after treatment with Valbenazine for a total of 6 weeks. Improvement in TD will be assessed as well and correlated with reduction in demoralization.
started
Oct 18, 2024
primary completion
Oct 18, 2025
completion
Oct 18, 2025
last updated
Jul 11, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol